Navigation Links
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
Date:10/13/2008

robiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, including the inability to enroll patients at anticipated rates, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
3. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
7. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
8. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
9. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
10. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
11. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... - FBR 1 st Annual Healthcare Conference ... on Wednesday, September 3 rd - Citi,s 9 ... on Thursday, September 4 th In ... of America Merrill Lynch Global Healthcare Conference at the Bank ...
(Date:8/20/2014)... Reportlinker.com announces that a new market ... The Impact of Healthcare Reform (PPACA) On ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The "Patient Protection and ... that affects virtually every aspect of health care, ... take effect now. IVD manufacturers who have different ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... is available in its catalogue: ... Key Trends and Opportunities to 2017 ... Synopsis The report provides in depth ... Canadian personal accident and health insurance segment, ...
Breaking Medicine Technology:PTC Therapeutics to Participate at Upcoming Investor Conferences 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23
... a specialty clinical stage pharmaceutical company focused on ... of the eye, today announced it has secured ... The funds will be used to complete a ... lead product, MC-1101.  Concurrently, MacuCLEAR has also entered ...
... BOSTON, Jan. 3, 2012  PAREXEL International Corporation (NASDAQ: ... of Fiscal Year 2012 on Monday, January 30, 2012 after ... available on PAREXEL,s website at www.PAREXEL.com and on ... PAREXEL will host a conference call and live webcast at ...
Cached Medicine Technology:MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership 2PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call 2
(Date:8/21/2014)... Aug. 21, 2014 Individuals with schizophrenia often have ... themselves, and a new study from San Francisco State ... assessing the amount of effort required to complete tasks. ... week in the Journal of Abnormal Psychology , ... patients with schizophrenia and help those patients function normally ...
(Date:8/21/2014)... Entries are now open for the 2014 HREI ... totally dedicated to recognizing excellence in the areas of ... deadline is Oct. 17. , The awards are being ... only national magazine entirely devoted to covering healthcare real ... HREI Insights Awards program last year and it was ...
(Date:8/21/2014)... 21, 2014 Recently it came to ... company located in Massachusetts has made public claims on ... marijuana patient verification system in the Massachusetts cannabis industry. ... to our growing and compassionate industry we must set ... claims are inaccurate. , MarijuanaDoctors.com has actually been ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... drug shows promise in treating respiratory syncytial virus (RSV), a ... are finally making major progress in being able to treat ... serious viral pneumonia, second only to influenza virus," said study ... University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... by their self-interest, humans do not protest being ... in Georgia State University,s Brains and Behavior Program ... are less concerned than previously believed about the ... published in the journal Brain Connectivity . ... affected by their self-interest, indicating the interest humans ...
Breaking Medicine News(10 mins):Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Influenced by self-interest, humans less concerned about inequity to others 2Health News:Influenced by self-interest, humans less concerned about inequity to others 3
... incidence of new diseases and rise in infectious diseases is ... led to an imbalance in between natural reservoirs and human ... spread of new virus infections such as SARS, bird flu ... to antibiotics and other drugs due to indiscriminate use of ...
... under increased pressure from charities for making it possible to increase ... tamoxifen//. Women suffering from the early stages of the disease are ... for two years were to switch over to anastrozole, one of ... a period of two and a half years, according to the ...
... recipient has undergone a further graft on Friday, even ... in Lyons, France, received a second transplant of bone ... had been successful, doctors said. This is meant to ... ,The technique was developed by Prof Jean-Michel Dubernard, ...
... stroke, three leading killers in the U.S., all dropped in ... ,Also, Americans' life expectancy increased again in 2003, up ... in 1990. ,Life expectancy in the U.S. has ... including advances in medicine and sanitation, and declines in unhealthy ...
... mother Bernadette Mimura, belonging to Ingleby Barwick Ingleby Barwick who ... disease//. She had refused life-saving treatment as it involved making ... the unborn baby, by the doctors. ,Being a ... a mild form of chemotherapy treatment with the object of ...
... of regulations was established by The Society for ... were basically for the welfare of the patients// ... doctors and other staff members. All the cardiological ... care in the sterilization unit. ,These ...
Cached Medicine News:Health News:Face transplant woman has new graft 2Health News:US life expectancy climbs to a new high 2
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
Medicine Products: